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Abstract Bcl I in the promoter polymorphism observed
within h-GR/NR3C1 gene may play an important role in the
development of bronchial asthma and resistance to GCs in
the severe bronchial asthma. The aim of the investigation
was to study the correlation between this h-GR/NR3C1 gene
polymorphism and occurrence of asthma in the population
of Polish asthmatics. Peripheral blood was obtained from 70
healthy volunteers and 59 asthma patients. Structuralized
anamnesis, spirometry and allergy skin prick tests were
performed in all participants. Genotyping was carried out
with PCR–RFLP method. In healthy, non-atopic population
variants of Bcl I: GG, GC, CC were found with frequency
0.129/0.471/0.400, respectively. In asthma patients Bcl I:
GG, GC, CC occurred with respective frequencies of 0.410/
0.462/0.128. Chi-square analysis revealed a signiﬁcantly
different (P\0.05) distribution between cases and controls
for the Bcl I polymorphism. The Bcl I polymorphism of h-
GR/NR3C1 gene is signiﬁcantly associated with bronchial
asthma, susceptibility to the development of severe form
and resistance to GCs in Polish population.
Keywords Glucocorticoid receptor   Glucocorticoid
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Introduction
Bronchial asthma is a disease with multifactor etiology [1].
The mutual correlations among the groups of factors pre-
disposing to the development of the disease and the prev-
alence of asthma are complex in character [2]. The
hereditary component of asthma is determined polygenet-
ically [3]. The environmental component is implied sig-
niﬁcantly by neuroimmune reactions occurring at the
molecular level. It should be emphasized that bronchial
asthma is a disorder whose primary cause can probably be
traced in the disturbed immunoregulatory mechanisms at
the lymphocyte level, with secondary overproduction of
IgE class antibodies and allergic inﬂammatory condition
[3]. Glucocorticosteroids (GCS) constitute the basic group
of medications used to control inﬂammatory conditions in
patients with bronchial asthma. They exert a multidirec-
tional and speciﬁc effect on various cell types. They
regulate the expression of speciﬁc genes within the cell
T. Pietras   P. Go ´rski
Department of Pneumology and Allergology, Medical University
of Lodz, Kopcin ´skiego 22, 90-153 Lodz, Poland
e-mail: cital200@wp.pl
P. Go ´rski
e-mail: pawel.gorski@umed.lodz.pl
M. Panek   D. Tworek   P. Kuna
Department of Internal Diseases, Asthma and Allergy, Medical
University of Lodz, Kopcin ´skiego 22, 90-153 Lodz, Poland
e-mail: michalmp@poczta.onet.pl
D. Tworek
e-mail: damian.tworek@gmail.com
P. Kuna
e-mail: pkuna@barlicki.internetdsl.pl
R. Wujcik
Faculty of Psychology, Academic School of Social Psychology
in Warsaw, Chodakowska, 19/31, Warsaw 03-815, Poland
e-mail: radoslaw.wujcik@swps.edu.pl
K. Oszajca   J. Szemraj (&)
Department of Medical Biochemistry, Medical University
of Lodz, Mazowiecka 6/8, Lodz 92-215, Poland
e-mail: jszemraj@csk.am.lodz.pl
K. Oszajca
e-mail: katarzyna.oszajca@umed.lodz.pl
123
Mol Biol Rep (2011) 38:3953–3958
DOI 10.1007/s11033-010-0512-5nuclei via the corticosteroid/receptor complex/receptor
(GCS/GR) [4].
Glucocorticosteroid resistance is a complex problem [5].
It may be constitutional in character, or develop as a sequel
to an inﬂammatory process. It should be emphasized that
each tissue represents different sensitivity to GCS. There
are serious doubts whether we are born with steroid-
resistant asthma, or we acquire it during our lifetime, i.e. if
it is dependent on genetic or environmental factors.
The genes involved in increased production of allergen-
speciﬁc IgE class antibodies (atopy), bronchial hyperreac-
tivity, production of inﬂammatory response mediators, and
Th1 and Th2 lymphocyte population sizes play a role in the
etiopathogenesis of the disease [6, 7]. It is notable that the
results of search for the gene or genes predisposing for
thedevelopmentofatopyorbronchialasthmaobtainedsofar
are not consistent, and the research is still going on.
The human glucocorticoid receptor gene/nuclear recep-
tor subfamily 3, group C, member 1 gene h-GR/NR3C1 is
localized on chromosome 5q31–q32 and consists of nine
exon [8]. The mRNA transcript for h-GR/NR3C1 gene
protein undergoes splicing, which leads to the formation of
four mRNA isoforms: GRa,G R b,G R d and GRc [9, 10].
The only active form of the receptor is GRa. The remaining
isoforms are post-transcriptional modiﬁcations of the h-
GR/NR3C1 gene lacking the full potential [3]. The gluco-
corticoid receptor is a protein made up of a single poly-
peptide chain consisting of 777 amino acids [11]. A few
domains can be distinguished within the receptor. Domain
C, which is the carrier of immunogenicity and other bio-
logical characteristics, is located between amino acids
1–421, which account for a half of the receptor size. The
central GR area (between amino acids 421–486) is
responsible for DNA binding (domain B). It contains cys-
teine residues forming complexes with zinc, facilitating
DNA binding and determining its tertiary structure. In the
terminal portion of the receptor molecule, there is a seg-
ment (domain A) which controls binding of a hormone
molecule—GCS [12]. The molecular mechanism of action
of GCS involves binding of the speciﬁc ligand/glucocor-
ticoid receptor to the sequences of regulator genes encod-
ing the synthesis of anti-inﬂammatory proteins determining
the clinical effects of GCS.
Resistance to GCS at the molecular level results from
many mechanisms modifying the function of GR in the
cells. Reduced response to drugs of this group can be
explained by decreased expression of GR, impairment of
their ability to bind DNA, or enhanced expression of
transcriptional factors.
Currently, a complex mechanism of GCS resistance
development in patients with severe bronchial asthma is
postulated. Schwartz et al. [13] associated it with various
mechanisms related to GR function, Carmichael et al. [14]
studied the density of complement receptors on monocytes
and demonstrated no changes in GR expression after
administration of GCS, Corrigan et al. [15] described
reduced GR afﬁnity to the ligand as a result of p38MAP
kinase activation by IL-2 and IL-4, Adcock et al. [16]
demonstrated development of GCS resistance associated
with increased AP-1 (activator protein 1) activity, or
increased afﬁnity of AP-1 to GR.
Polymorphisms present within the h-GR/NR3C1 gene
may inhibit formation of GR/GCS complexes, reduce
transcription and cause transrepression of the genes
encoding proteins synthesized within the framework of
cellular response to GCS [17]. Bcl I RFLP is formed as a
result of changes in a single base. A C/G single nucleotide
polymorphism (SNP) within the h-GR/NR3C1 gene pro-
moter has been localized in the intron 647 bp away from
the exon/intron binding site. Allele G is particularly asso-
ciated with sensitivity to GCS. It increases the cellular
response to GCS and occurs less frequently than allele C
[17–19]. Polymorphism Bcl I( C [G) within h-GR/NR3C1
gene promoter demonstrates correlations with sensitivity to
steroids, multiple sclerosis and hypothalamo-pituitary-
adrenal axis [20].
Because of complex etiopathogenesis of bronchial
asthma, its heterogeneous nature, incomplete gene pene-
tration, presence of phenocopies, differentiated gene
expression and gene–gene interactions, thorough investi-
gation of molecular mechanisms leading to the develop-
ment of bronchial asthma is a difﬁcult problem, which
requires continuous evaluation [21].
The aim of the investigation was to study the correlation
between Bcl I single nucleotide polymorphism of h-GR/
NR3C1 gene promoter and occurrence of bronchial asthma
in the Polish population.
Materials and methods
The study was approved by the local ethics committee
(Consent of Research Review Board at the Medical Uni-
versity of Lodz, Poland, No RNN/133/09/KE). At the
commencement of the study, participants were invited to
attend voluntarily. Before admission, written informed
consent was obtained from every patient.
The study was conducted in a group of 55 patients with
bronchial asthma. Asthma diagnosis was established
according to GINA recommendations, based on clinical
asthma symptoms and lung function test. The control arm
included a group of 70 healthy adults, who met the fol-
lowing criteria: no history or symptoms of either bronchial
asthma, or other pulmonary diseases, no history or symp-
toms of allergy, no history or symptoms of atopic derma-
titis, no history or signs of hypersensitivity to aspirin,
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123negative results of skin tests for 12 common allergens, no
ﬁrst-degree relatives with bronchial asthma or atopic
disorders.
Venous blood samples were collected from the partici-
pants onto EDTAK3, DNA was obtained from peripheral
blood leukocyte fraction. The genetic material was isolated
using Wizard DNA Isolation Kit (Promesa, Madison, WI)
according to the guidelines provided by the manufacturer.
The investigated polymorphisms were analyzed using
PCR–RFLP method.
Ampliﬁcation of DNA segments for Bcl I polymorphism
was conducted using a forward primer (50-GAG AAA TTC
ACC CCT ACC AAC-30) and a reverse primer (50-AGA
GCC CTA TTC TTC AAA CTG-30) according to standard
PCR protocol. Starter binding to complementary DNA
matrix sites was accomplished at 56C. Ampliﬁed DNA
sequences of 418 bp length were obtained. The material
was incubated with Bcl I restriction enzyme (New England
Biolabs, Neverly, MA) at 50C for 10 h. DNA fragments
containing 263 and 151 bp identiﬁed as a set of represen-
tative, typical (wild type) alleles were obtained, as well as
segments with 418, 263 and 151 bp. RFLP of 418 bp
length was identiﬁed as the set of polymorphic alleles.
RFLP products were separated by electrophoresis on 2%
agarose gel, stained with ethidine bromide and observed in
UV light. Representative, typical homozygotes, as well as
heterozygotes were sequenced and used as internal control.
The obtained results were subjected to descriptive sta-
tistical analysis with calculation of arithmetic means
and standard deviations. The signiﬁcance of differences
between mean values was determined by means of Chi
2,
with P\0.05 adopted as the signiﬁcance level.
Results
The control group consisted of 70 healthy volunteers
(women 48.6%, men 51.4%), aged on the average
63.11 years, SD ± 5.00, with the youngest subject 55 and
the oldest 75 years old, bias 0.19, standard error of the bias
0.28. The following frequencies of Bcl I polymorphism of
h-GR/NR3C1 gene promoter—GG, GC, CC—were
obtained: 0.129/0.471/0.400, respectively. The group of
asthmatic patients consisted of 59 healthy volunteers
(women 71.2%, men 28.8%), aged on the average
50.81 years, SD ± 13.65, with the youngest subject 23 and
the oldest 77 years old, bias -0.32, standard error of the
bias 0.31. The following frequencies of Bcl I polymor-
phism of h-GR/NR3C1 gene promoter—GG, GC, CC—
were obtained: 0.436/0.455/0.109, respectively. Compre-
hensive comparison of the analyzed groups is presented in
Table 1.
The alleles of the investigated polymorphism in both
groups demonstrate distribution consistent with Hardy–
Weinberg equilibrium [22–24]. Figure 1 illustrates de
Finetti distributions of the investigated genotypes [25–27].
Signiﬁcant statistical differences between the investi-
gated genotypes were demonstrated (P\0.05). Patients
with bronchial asthma presented allele G of the investigated
Bcl I polymorphism signiﬁcantly more frequently. The fre-
quency of allele G versus C correlated with increased
occurrence of bronchial asthma in the investigated popula-
tion (OR = 3.44, CI: 95% conﬁdence interval, CI = 2.03–
5.81, v
2 = 22.08, P = 2.61e-06). Genotype GG versus CC
was characterized by OR = 12.44, CI: 95% conﬁdence
interval,CI = 3.87–540.01,v
2 = 20.55withP = 5.82e-06.
The carriers of allele G (GG ? GC) versus CC developed
bronchial asthma signiﬁcantly more often (OR = 5.44, CI:
95% conﬁdence interval, CI = 2.05–14.41, v
2 = 13.16,
P = 0.00029). Mutation SNP G/C within the Bcl I poly-
morphism of h-GR/NR3C1 gene promoter had a protective
effect and reduced the risk of developing bronchial asthma.
Theoccurrenceofallele CversusGreduced inastatistically
signiﬁcant manner the risk of the disease (OR = 0.29, CI:
95% conﬁdence interval, CI = 0.17–0.049, v
2 = 22.08,
P = 2.61e-06). The carriers of allele C (CC ? CG) devel-
oped bronchial asthma signiﬁcantly less frequently
(OR = 0.08, CI: 95% conﬁdence interval, CI = 0.02-0.25,
v
2 = 20.55, P = 5.82e-06.) Table 2 contains the descrip-
tion of statistics for the analyzed genotype frequencies.
No intra- and inter-group correlations among the gender,
occurrenceofallergyandage(P[0.05)weredemonstrated.
Table 1 Descriptive statistics of the analyzed parameters in controls
and cases
Parameter Control group Group of bronchial
asthma patients
N7 0 5 9
Gender 34 women:36 men 42 women:17 men
Gender (%) 48.6 women:51.4
men
71.1 women:28.8
men
Mean age 63.11 years 50.81 years
SD for age ±5.00 years ±13.65 years
Min. age 55 years 23 years
Max. age 75 years 77 years
Obliquity 0.19 -0.32
Obliquity standard
error
0.28 0.31
Median 63.00 54.00
Polymorphism of Bcl I
GG 0.129 0.436
GC 0.471 0.455
CC 0.400 0.109
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Bronchial asthma is a disease with multifactor etiology. It
develops on the background of mutual interactions between
genetic and environmental factors. Numerous studies have
conﬁrmed that various responses to GCS can be observed
in healthy population. The genetic variability with respect
to SNPs and mutual gene–gene interactions are the
important elements in the development of bronchial
asthma. The key loci determining the development of this
disease are localized in chromosome 5q31–q32 (gene
encoding IL-3, IL-4, IL-5, IL-9, IL-13, GM-CSF, CD14,
LTC4S as well as h-GR/NR3C1 and b2-adrenergic
receptor).
The tissue speciﬁcity of GCS effect on the transcription
of genes encoding the synthesis of anti-inﬂammatory pro-
teins, determining the therapeutic effect, is dependent on
many factors. Numerous regulatory elements of DNA
within the h-GR/NR3C1 gene promoter, coactivator pro-
teins, cAMP activity, as well as complex protein kinase
signal pathways play the crucial role here [3, 28–32].
Binding of the GCS-GR complex with the DNA of regu-
lator gene sequences is a key signal for co-activator pro-
teins CBP (CREB Winding protein) and pCAF (CBP
associated factor) as well as SRC-1 (steroid receptor
coactivator-1) [1, 3]. Coactivator proteins unwind the DNA
strand, combine with RNA polymerase II and bind with the
TATA sequence (TATA-box binding protein, TBP). These
interaction lead to initiation of transcription [1, 3]. In view
of the discussed processes, the interactions between GCS-
GR homodimer and regulatory DNA sequences within the
h-GR/NR3C1 gene promoter seem to play the key role
[3, 17–20]. Clinical observations and studies conducted by
many investigators allow to put forward a hypothesis
concerning a cause-and-result relationship between the
presence of SNPs within the h-GR/NR3C1 gene promoter,
and the development of bronchial asthma and resistance to
GCS [3, 18–20, 33].
The presented study emphasizes the role of Bcl I poly-
morphism of h-GR/NR3C1 gene promoter in the etio-
pathogenesis of bronchial asthma. It should be emphasized
that the analysis of SNPs conﬁrmed the correlation
between the DNA promoter sequences of the investigated
gene and the frequency of bronchial asthma. Undoubtedly,
too small sized of the studied groups are still a shortcom-
ing of our project. Nevertheless, the observed variations
indicate allele G as a factor promoting the development of
bronchial asthma. Mutation G/C within the gene promoter
is protective in character and correlates with reduced fre-
quency of the disease. The study needs to be conﬁrmed in
large populations of asthmatic patients, especially those
with treatment-resistant asthma. It is noteworthy that the
signiﬁcantly increasing prevalence of steroid resistance
(35–50%) among patients with severe asthma requires not
Fig. 1 De Finetti diagram with
Hardy–Weinberg parabola was
drawn using The Helmholtz
Zentrum Mu ¨nchen free
software, Germany. Description
of diagram: black line—
controls; blue lines— cases.
(Color ﬁgure online)
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domains of h-GR/NR3C1 gene promoter, but also assess-
ment of gene couplings crucial for the development of
asthma and resistance to treatment.
The latest reports pay attention to the role of gene
polymorphisms, genetic variations in receptor expressed
and extra receptor transcriptional factors in the etiopatho-
genesis of asthma and steroid resistance phenomenon.
Supposedly, disturbances at the level of AP-1 afﬁnity to
GR are one of the molecular pathways of cellular resistance
to the effect of GCS. Transcriptional factors, and among
them AP-1 (activator protein-1) and nuclear factor kappa B
(NF-kB) in particular, are the modulators of activity of
numerous genes responsible for the development of
inﬂammation, which, binding to GR block GCS-GR
binding with DNA sequences of speciﬁc response elements
(GRE) [34–38].
Conclusions
To date, it has been impossible to deﬁne precisely the role
of single loci, regions of the particular genes, and indi-
vidual SNPs of the h-GR/NR3C1 gene in the etiopatho-
genesis of bronchial asthma and response of the patients to
GCS therapy. In view of the applicable paradigms of
modern genetics, the key role is attributed to determination
of the gene structure and its allelic variants, as well as to
assessment of the correlation between the level of expres-
sion and biological properties of proteins.
Marker RFLP of the h-GR/NR3C1 gene is an impor-
tant factor in the development of asthma. In the Authors’
opinion, allele G of Bcl I polymorphism of h-GR/NR3C1
gene promoter demonstrates a marked correlation with
the development of bronchial asthma. Its evaluation
requires intensive research on hereditary factors linking
the particular SNPs with the development of bronchial
asthma.
It should be emphasized that no studies concerning the
frequency of h-GR/NR3C1 glucocorticoid receptor gene
polymorphisms in bronchial asthma patients, including
those with severe, treatment-resistant asthma, have been
conducted in Poland to date.
The Authors believe that genotyping utilizing the PCR–
RFLP techniques will allow in the future to create a
bronchial asthma patient proﬁle—phenotype of the Polish
patients. The presented study is a preliminary stage for
more profound analysis of correlations between the prev-
alence of the particular allelic variants of the h-GR/NR3C1
gene and the development of bronchial asthma, including
severe, treatment-resistant forms of the disease.
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Table 2 Descriptive statistics of the analyzed allele of Bcl I polymorphism in controls and cases
Allele frequencies difference Heterozygous Homozygous Allele positivity Armitage’s trend test
[G] vs. [C] [GC] vs. [CC] [GG] vs. [CC] [GG ? GC] vs. [CC] Common odds ratio
Risk allele G
OR = 3.44 OR = 3.53 OR = 12.44 OR = 5.44 OR = 3.52
CI = [2.03–5.81] CI = [1.27–9.83] CI = [3.87–40.01] CI = [2.05–14.41]
v
2 = 22.08 v
2 = 6.22 v
2 = 20.55 v
2 = 13.16 v
2 = 20.60
P = 2.613e-06 P = 0.01265 P = 5.820e-06 P = 0.00029 P = 5.661e-06
Allele frequencies difference Heterozygous Homozygous Allele positivity Armitage’s trend test
[C] vs. [G] [GC] vs. [GG] [CC] vs. [GG ? GC] [GC ? CC] vs. [GG] Common odds ratio
Risk allele C
OR = 0.29 OR = 0.28 OR = 0.08 OR = 0.19 OR = 0.28
CI = [0.17–0.49] CI = [0.11–0.71] CI = [0.02–0.25] CI = [0.07–0.45]
v
2 = 22.08 v
2 = 7.43 v
2 = 20.55 v
2 = 15.02 v
2 = 20.60
P = 2.613e-06 P = 0.00642 P = 5.820e-06 P = 0.00011 P = 5.661e-06
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